Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$39.47 +2.2%	$31.95	$16.50 ▼ $43.58	$3.44B	N/A	47,388 shs	5,541 shs
BBIO BridgeBio Pharma	$46.72 -0.8%	$39.30	$21.72 ▼ $48.68	$8.87B	1.15	2.54 million shs	693,489 shs
LEGN Legend Biotech	$42.11 +5.9%	$33.41	$27.34 ▼ $60.87	$7.74B	0.19	1.37 million shs	2.59 million shs
TGTX TG Therapeutics	$39.16 +0.8%	$36.22	$16.65 ▼ $46.48	$6.22B	1.91	2.86 million shs	854,474 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+5.06%	-7.76%	+20.20%	+106.30%	+3,861,999,900.00%
BBIO BridgeBio Pharma	+0.28%	+2.44%	+14.49%	+39.06%	+61.03%
LEGN Legend Biotech	+0.40%	+0.73%	+10.91%	+21.19%	-28.89%
TGTX TG Therapeutics	+2.32%	+2.43%	+9.01%	+1.36%	+72.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	4.6415 of 5 stars	4.5	1.0	0.0	3.9	3.1	3.3	0.6
LEGN Legend Biotech	3.6478 of 5 stars	4.5	3.0	0.0	0.0	3.2	1.7	0.6
TGTX TG Therapeutics	3.395 of 5 stars	2.4	0.0	0.0	3.5	1.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
BBIO BridgeBio Pharma	3.00	Buy	$61.20	30.98% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$73.33	74.13% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	11.85% Upside

Current Analyst Ratings Breakdown

Latest AAPG, BBIO, LEGN, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	LEGN Legend Biotech	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/17/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/10/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00 ➝ $81.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
7/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/2/2025	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00 ➝ $54.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	3.51	N/A	N/A	$0.48 per share	82.23
BBIO BridgeBio Pharma	$221.90M	39.98	N/A	N/A	($7.71) per share	-6.06
LEGN Legend Biotech	$728.30M	10.63	N/A	N/A	$5.70 per share	7.39
TGTX TG Therapeutics	$329M	18.90	$0.12 per share	316.43	$1.43 per share	27.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	163.21	39.16	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest AAPG, BBIO, LEGN, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	LEGN Legend Biotech	-$0.18	N/A	N/A	N/A	$237.49 million	N/A
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
BBIO BridgeBio Pharma	N/A	4.57	4.54
LEGN Legend Biotech	0.30	5.20	5.07
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
BBIO BridgeBio Pharma	99.85%
LEGN Legend Biotech	70.89%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
BBIO BridgeBio Pharma	18.20%
LEGN Legend Biotech	0.02%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

AAPG, BBIO, LEGN, and TGTX Headlines

Recent News About These Companies

Sigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 17 at 5:25 AM | marketbeat.com

Bank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 15 at 3:35 AM | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs

July 12, 2025 | theglobeandmail.com

Banque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)

July 11, 2025 | marketbeat.com

TG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90

July 10, 2025 | msn.com

TG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite Rating

July 10, 2025 | msn.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

July 10, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLC

July 9, 2025 | marketbeat.com

Axsome Therapeutics Sees Relative Strength Rating Climb To 79

July 8, 2025 | msn.com

Penserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

New York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 7, 2025 | marketbeat.com

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5, 2025 | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2, 2025 | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2, 2025 | msn.com

Cramer's Lightning Round: TG Therapeutics is a buy

June 30, 2025 | nbcnewyork.comN

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund

June 30, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Financials - Morningstar

June 28, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, BBIO, LEGN, and TGTX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$39.47 +0.85 (+2.20%)

As of 03:20 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

BridgeBio Pharma NASDAQ:BBIO

$46.72 -0.38 (-0.80%)

As of 03:56 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Legend Biotech NASDAQ:LEGN

$42.11 +2.36 (+5.94%)

As of 03:56 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

TG Therapeutics NASDAQ:TGTX

$39.16 +0.32 (+0.82%)

As of 03:56 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time